26,886 Shares in Vericel Co. (NASDAQ:VCEL) Purchased by Zions Bancorporation N.A.

Zions Bancorporation N.A. acquired a new stake in shares of Vericel Co. (NASDAQ:VCEL - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 26,886 shares of the biotechnology company's stock, valued at approximately $1,234,000. Zions Bancorporation N.A. owned approximately 0.06% of Vericel as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. UniSuper Management Pty Ltd purchased a new position in shares of Vericel in the first quarter worth about $595,000. BNP Paribas Financial Markets grew its holdings in Vericel by 99.7% in the 1st quarter. BNP Paribas Financial Markets now owns 111,760 shares of the biotechnology company's stock valued at $5,814,000 after buying an additional 55,796 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Vericel by 10.9% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,021,695 shares of the biotechnology company's stock worth $53,149,000 after acquiring an additional 100,797 shares during the period. Silvercrest Asset Management Group LLC purchased a new stake in shares of Vericel in the first quarter valued at about $6,538,000. Finally, Geneva Capital Management LLC raised its stake in Vericel by 43.6% during the first quarter. Geneva Capital Management LLC now owns 679,165 shares of the biotechnology company's stock worth $35,330,000 after purchasing an additional 206,202 shares during the period.

Insiders Place Their Bets

In other news, CEO Dominick Colangelo sold 17,500 shares of the firm's stock in a transaction that occurred on Thursday, July 18th. The shares were sold at an average price of $51.40, for a total transaction of $899,500.00. Following the transaction, the chief executive officer now directly owns 220,937 shares in the company, valued at $11,356,161.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CEO Dominick Colangelo sold 17,500 shares of the firm's stock in a transaction dated Thursday, July 18th. The stock was sold at an average price of $51.40, for a total transaction of $899,500.00. Following the transaction, the chief executive officer now owns 220,937 shares of the company's stock, valued at $11,356,161.80. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Sean C. Flynn sold 6,772 shares of the business's stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $45.02, for a total value of $304,875.44. Following the completion of the transaction, the insider now owns 487 shares in the company, valued at approximately $21,924.74. The disclosure for this sale can be found here. Insiders have sold a total of 46,291 shares of company stock valued at $2,329,169 over the last quarter. Company insiders own 5.20% of the company's stock.

Vericel Price Performance

Shares of NASDAQ VCEL traded up $1.60 during midday trading on Friday, hitting $45.87. 329,593 shares of the company's stock were exchanged, compared to its average volume of 438,542. The firm's fifty day simple moving average is $48.41 and its 200-day simple moving average is $47.40. The company has a market cap of $2.25 billion, a PE ratio of -4,582.42 and a beta of 1.67. Vericel Co. has a twelve month low of $30.18 and a twelve month high of $54.10.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its earnings results on Thursday, August 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). The business had revenue of $52.70 million during the quarter, compared to analysts' expectations of $52.59 million. Vericel had a net margin of 0.37% and a return on equity of 0.35%. The company's revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.11) EPS. Equities analysts anticipate that Vericel Co. will post 0.12 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Canaccord Genuity Group started coverage on Vericel in a report on Friday, August 9th. They issued a "buy" rating and a $57.00 price objective on the stock. StockNews.com raised shares of Vericel from a "sell" rating to a "hold" rating in a research note on Thursday, September 5th. Truist Financial boosted their price target on shares of Vericel from $56.00 to $57.00 and gave the company a "buy" rating in a research note on Tuesday, July 16th. Canaccord Genuity Group initiated coverage on shares of Vericel in a research report on Friday, August 9th. They set a "buy" rating and a $57.00 price objective for the company. Finally, BTIG Research decreased their price target on Vericel from $56.00 to $55.00 and set a "buy" rating on the stock in a research note on Monday, July 15th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $55.75.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.